CobraZol Roll-on Topical Gel
- Manufacturer
- Nature's Innovation, Inc.
- Effective date
- 2021-01-14
- Label type
- HUMAN OTC DRUG LABEL
- Version
- 3
- Source
- legacy-cache
- Hydrated at
- 2026-08-01 22:56:25
Label at a glance#
Contacts and useful links#
Label contents#
Full prescribing information#
OTC - ACTIVE INGREDIENT SECTION
Active Ingredients
Arnica montana (Moutain arnica) 1X HPUS
Capsicum annum (Cayenne pepper) 2X HPUS
Crotalus horridus (Rattlesnake venom) 6X HPUS
Lachesis muta (Bushmaster venom) 8X HPUS
Naja tripudians (Indian Cobra venom) 5X HPUS
The letters HPUS indicate the component(s) in this product is (are) officially monographed in the Homeopathic Pharmacopeia of the United States.
OTC - PURPOSE SECTION
Purpose
Nerve Injury, Spasms and Muscular Pain
Aching Muscle Symptom Relief
Analgesic
Analgesic
Analgesic
INDICATIONS & USAGE SECTION
UsesSymptomatic relief of muscle, joint neuralgia and arthritis pain and stiffness.
WARNINGS SECTION
Warnings
For External Use Only.
OTC - STOP USE SECTION
- If symptoms persist or worsen, discontinue use and seek medical attention.
OTHER SAFETY INFORMATION
- This product contains Capsicum, avoid contact with eyes. If product gets into eyes, flushy with water. Seek medical attention.
OTC - DO NOT USE SECTION
- Do not use on open wounds.
OTC - PREGNANCY OR BREAST FEEDING SECTION
- Pregnant or nursing women and children should not use this product unless advised by a physician.
OTC - ASK DOCTOR SECTION
- If swallowed, get medical help or contact a Poison Control Center right away.
OTC - KEEP OUT OF REACH OF CHILDREN SECTION
- Keep out of the reach of children.
DOSAGE & ADMINISTRATION SECTION
Directions
- Roll gel directly onto affected area.
- Rub thoroughly into area with pain.
- Wash hands immediately to prevent numbing effect and contact with capsicum in eyes.
- Use 3-4 times per day for 1st week. Use as needed thereafter to relieve discomfort.
- Allow several days for maximum effect.
OTHER SAFETY INFORMATION
Other Information
- Do not use if safety band is broken.
- Intended for use in cases of recurring pain.
- This product is NOT intended to treat disease. It assists in providing temporary relief.
- This product is for temporary relief of mild to moderate chronic pain.
INACTIVE INGREDIENT SECTION
Inactive Ingredients
Benzalkonium Chloride, Boswellia Serrata Resin Extract (Indian Franckincense), Curcuma Longa Root Extract (Curcumin), Glucono Delta Lactone, Isopropyl Alcohol, Menthyl Lactate, Methylcellulose, MSM (Methylsulfonylmethane), Oleic Acid, Propylene Glycol, Purified Water
OTC - QUESTIONS SECTION
Questions? Call 866-371-2499
Manufactured by: Nature's Innovation, Inc.
5317 Palmero Ct., Buford, GA 30518
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
for Chronic Pain Relief
CobraZol
Roll-on Topical Gel
HOMEOPATHIC
- Scent Free
- Analgesic*
- Anti-inflammatory*
- Neuralgia*
- Arthritis Pain*
- Muscle & Joint Pain*
Patent Pending
Net Wt. 3.0 oz. (88.721 mL)
DailyMed Dashboard NDC Coverage#
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| ARNICA MONTANA | ACTIVE INGREDIENT | O80TY208ZW | 1 | |
| CAPSICUM | ACTIVE INGREDIENT | 00UK7646FG | 1 | |
| CROTALUS HORRIDUS HORRIDUS VENOM | ACTIVE INGREDIENT | YHA2XLJ956 | 1 | |
| LACHESIS MUTA VENOM | ACTIVE INGREDIENT | VSW71SS07I | 1 | |
| NAJA NAJA VENOM | ACTIVE INGREDIENT | ZZ4AG7L7VM | 1 | |
| ARNICA MONTANA | ACTIVE MOIETY | O80TY208ZW | 1 | |
| CAPSICUM | ACTIVE MOIETY | 00UK7646FG | 1 | |
| CROTALUS HORRIDUS HORRIDUS VENOM | ACTIVE MOIETY | YHA2XLJ956 | 1 | |
| LACHESIS MUTA VENOM | ACTIVE MOIETY | VSW71SS07I | 1 | |
| NAJA NAJA VENOM | ACTIVE MOIETY | ZZ4AG7L7VM | 1 | |
| BENZALKONIUM CHLORIDE | INACTIVE INGREDIENT | F5UM2KM3W7 | 1 | |
| DIMETHYL SULFONE | INACTIVE INGREDIENT | 9H4PO4Z4FT | 1 | |
| GLUCONOLACTONE | INACTIVE INGREDIENT | WQ29KQ9POT | 1 | |
| INDIAN FRANKINCENSE | INACTIVE INGREDIENT | 4PW41QCO2M | 1 | |
| ISOPROPYL ALCOHOL | INACTIVE INGREDIENT | ND2M416302 | 1 | |
| METHYL LACTATE, L- | INACTIVE INGREDIENT | 0379G9C44S | 1 | |
| METHYLCELLULOSE (1500 CPS) | INACTIVE INGREDIENT | P0NTE48364 | 1 | |
| OLEIC ACID | INACTIVE INGREDIENT | 2UMI9U37CP | 1 | |
| PROPYLENE GLYCOL | INACTIVE INGREDIENT | 6DC9Q167V3 | 1 | |
| TURMERIC | INACTIVE INGREDIENT | 856YO1Z64F | 1 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 1 |
Products#
Every source-derived product name is available through these pages.
- CobraZol
- Arnica montana, Capsicum annum, Crotalus horridus, Lachesis muta, Naja tripudians
- ARNICA MONTANA
- CAPSICUM
- CROTALUS HORRIDUS HORRIDUS VENOM
- LACHESIS MUTA VENOM
- NAJA NAJA VENOM
- BENZALKONIUM CHLORIDE
- INDIAN FRANKINCENSE
- TURMERIC
- GLUCONOLACTONE
- ISOPROPYL ALCOHOL
- METHYL LACTATE, L-
- DIMETHYL SULFONE
- OLEIC ACID
- PROPYLENE GLYCOL
- WATER
- METHYLCELLULOSE (1500 CPS)
NDC Codes#
| Product NDC | Package NDC |
|---|---|
| 10893-900 | 10893-900-03 |
Ingredients#
Every source-derived ingredient row is available through these pages.
Source Document#
Inactive ingredient matches#
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 63.4 %w/v | ||
| ISOPROPYL ALCOHOL | ISOPROPYL ALCOHOL | ND2M416302 | GEL / TOPICAL | 75 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SYRUP / ORAL | 5700 mg | ||
| BENZALKONIUM CHLORIDE | BENZALKONIUM CHLORIDE | F5UM2KM3W7 | GEL / OPHTHALMIC | 0.01 %w/w | ||
| BENZALKONIUM CHLORIDE | BENZALKONIUM CHLORIDE | F5UM2KM3W7 | SUSPENSION/ DROPS / AURICULAR (OTIC) | 0.02 %w/v | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SUSPENSION / TOPICAL | 5.28 %w/v | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 19 mg | ||
| BENZALKONIUM CHLORIDE | BENZALKONIUM CHLORIDE | F5UM2KM3W7 | SUSPENSION/ DROPS / TOPICAL | NA | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SOLUTION / ORAL | 22602 mg | ||
| BENZALKONIUM CHLORIDE | BENZALKONIUM CHLORIDE | F5UM2KM3W7 | SOLUTION/ DROPS / OPHTHALMIC | 1 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | EMULSION / TOPICAL | 8 %w/w | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SOLUTION / RESPIRATORY (INHALATION) | 25 %w/w | ||
| OLEIC ACID | OLEIC ACID | 2UMI9U37CP | CAPSULE / ORAL | 8759 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | INJECTION / SUBCUTANEOUS | 1.4 %w/v | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | TABLET, EXTENDED RELEASE / ORAL | 9 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SPRAY, METERED / NASAL | 240 mg | ||
| BENZALKONIUM CHLORIDE | BENZALKONIUM CHLORIDE | F5UM2KM3W7 | SOLUTION/ DROPS / AURICULAR (OTIC) | 0 %w/v | ||
| BENZALKONIUM CHLORIDE | BENZALKONIUM CHLORIDE | F5UM2KM3W7 | LIQUID / NASAL | 0.2 mg/1ml | ||
| OLEIC ACID | OLEIC ACID | 2UMI9U37CP | CREAM / TOPICAL | 25 %w/w | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SOLUTION / DENTAL | 2 %w/w | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | INJECTION, SOLUTION / INTRAVENOUS | 4000 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | TABLET, DELAYED RELEASE / ORAL | 36 mg | ||
| BENZALKONIUM CHLORIDE | BENZALKONIUM CHLORIDE | F5UM2KM3W7 | SOLUTION / TOPICAL | 0.02 %w/v | ||
| OLEIC ACID | OLEIC ACID | 2UMI9U37CP | SOLUTION / TOPICAL | 7.4 %w/w | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | FILM, EXTENDED RELEASE / TRANSDERMAL | 58.13 mg | ||
| OLEIC ACID | OLEIC ACID | 2UMI9U37CP | SYSTEM / TRANSDERMAL | 22 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | OINTMENT, AUGMENTED / TOPICAL | 714 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | INJECTION, SOLUTION / INTRAMUSCULAR | 4000 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | INJECTION / INTRAVENOUS | 16624 mg | ||
| ISOPROPYL ALCOHOL | ISOPROPYL ALCOHOL | ND2M416302 | SWAB / TOPICAL | 43.9 %w/w | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SUSPENSION/ DROPS / OPHTHALMIC | 0.75 %w/v | ||
| METHYLCELLULOSE (1500 CPS) | METHYLCELLULOSE (1500 MPA.S) | P0NTE48364 | TABLET / ORAL | 319 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SOLUTION, CONCENTRATE / INTRAVENOUS | 50.33 %w/v | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SOLUTION / OPHTHALMIC | 1 %w/v | ||
| OLEIC ACID | OLEIC ACID | 2UMI9U37CP | GEL, METERED / TOPICAL | 88 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | GEL / TRANSDERMAL | 500 mg | ||
| BENZALKONIUM CHLORIDE | BENZALKONIUM CHLORIDE | F5UM2KM3W7 | SOLUTION/ DROPS / TOPICAL | 0.01 %w/v | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | TABLET, COATED / ORAL | 16 mg | ||
| OLEIC ACID | OLEIC ACID | 2UMI9U37CP | INJECTION, EMULSION / INTRAVENOUS | 0.03 %w/v | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | TABLET / ORAL | 64 mg | ||
| ISOPROPYL ALCOHOL | ISOPROPYL ALCOHOL | ND2M416302 | TABLET, EXTENDED RELEASE / ORAL | NA | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | DROPS / ORAL | 200 mg/1ml | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | OINTMENT / TOPICAL | 5148 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | CLOTH / TOPICAL | 0.03 mg/mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | TABLET, FILM COATED / ORAL | 96 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | INJECTION, SOLUTION / SUBCUTANEOUS | 1.4 %w/v | ||
| BENZALKONIUM CHLORIDE | BENZALKONIUM CHLORIDE | F5UM2KM3W7 | SUSPENSION / AURICULAR (OTIC) | 0.01 %w/v | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | CAPSULE, DELAYED RELEASE / ORAL | 1.7 mg | ||
| OLEIC ACID | OLEIC ACID | 2UMI9U37CP | FILM, EXTENDED RELEASE / TRANSDERMAL | 10 mg | ||
| BENZALKONIUM CHLORIDE | BENZALKONIUM CHLORIDE | F5UM2KM3W7 | SOLUTION / NASAL | 40.46 mg/100ml | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | FILM / BUCCAL | 1.48 mg | ||
| BENZALKONIUM CHLORIDE | BENZALKONIUM CHLORIDE | F5UM2KM3W7 | INJECTION / INTRAMUSCULAR | 1 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | CONCENTRATE / ORAL | 7000 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | GEL / OPHTHALMIC | 0.44 %w/w | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SUSPENSION / RECTAL | 90400 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SOLUTION/ DROPS / AURICULAR (OTIC) | ADJ PH | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | LOTION / TOPICAL | 3392 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | INJECTION / INTRAMUSCULAR | 7459 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SOLUTION / TOPICAL | 4886 mg | ||
| BENZALKONIUM CHLORIDE | BENZALKONIUM CHLORIDE | F5UM2KM3W7 | SHAMPOO / TOPICAL | 0.2 %w/w |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 963c5e8e-3744-4ca0-bcc0-43357d34432a | 37fb2575-8af0-4a50-b406-faae5b824bc4 | 2025-07-25 | Warnings | 37fb2575-8af0-4a50-b406-faae5b824bc4 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.

